Bjorn Thies - NeuPath Health Vice Culture
| NPTH Stock | CAD 0.20 0.01 4.76% |
Executive
Bjorn Thies is Vice Culture of NeuPath Health
| Address | 6400 Millcreek Drive, Mississauga, ON, Canada, L5N 3E7 |
| Phone | 905 858 1368 |
| Web | https://www.neupath.com |
NeuPath Health Management Efficiency
The company has return on total asset (ROA) of 0.0146 % which means that it generated a profit of $0.0146 on every $100 spent on assets. This is way below average. NeuPath Health's management efficiency ratios could be used to measure how well NeuPath Health manages its routine affairs as well as how well it operates its assets and liabilities. At this time, NeuPath Health's Net Tangible Assets are fairly stable compared to the past year. Total Current Assets is likely to climb to about 12.4 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 34.6 M in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Elena Korablina | JPMorgan Chase Co | 51 | |
| Alice Jolla | Microsoft Corp CDR | 59 | |
| Sripada Shivananda | JPMorgan Chase Co | 52 | |
| Alexander Schultz | Meta Platforms CDR | 42 | |
| Stephanie Wissink | Walmart Inc CDR | N/A | |
| Andrew Bosworth | Meta Platforms CDR | 43 | |
| Michael Pille | Berkshire Hathaway CDR | N/A | |
| Kevan Parekh | Apple Inc CDR | 53 | |
| Jennifer JD | Meta Platforms CDR | 55 | |
| Michael Guptan | Walmart Inc CDR | N/A | |
| Ron Okamoto | Apple Inc CDR | N/A | |
| Tony Maggiore | JPMorgan Chase Co | N/A | |
| Donna Morris | Walmart Inc CDR | 56 | |
| Henry Moniz | Meta Platforms CDR | 60 | |
| Jennifer Newstead | Meta Platforms CDR | 54 | |
| David Hansson | JPMorgan Chase Co | 51 | |
| Jennifer Driscoll | EXXON MOBIL CDR | 58 | |
| Stacey Friedman | JPMorgan Chase Co | 55 | |
| Janelle Gale | Meta Platforms CDR | N/A | |
| Hossein Nowbar | Microsoft Corp CDR | N/A | |
| Matthew Miner | Walmart Inc CDR | N/A | |
Management Performance
| Return On Equity | 3.0E-4 | ||||
| Return On Asset | 0.0146 |
NeuPath Health Leadership Team
Elected by the shareholders, the NeuPath Health's board of directors comprises two types of representatives: NeuPath Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NeuPath. The board's role is to monitor NeuPath Health's management team and ensure that shareholders' interests are well served. NeuPath Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NeuPath Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph MBA, Interim Director | ||
| Bjorn Thies, Vice Culture |
NeuPath Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NeuPath Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NeuPath Stock Analysis
When running NeuPath Health's price analysis, check to measure NeuPath Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuPath Health is operating at the current time. Most of NeuPath Health's value examination focuses on studying past and present price action to predict the probability of NeuPath Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuPath Health's price. Additionally, you may evaluate how the addition of NeuPath Health to your portfolios can decrease your overall portfolio volatility.